Physician Search
 |
 |
 |
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Lymphoma
Lymphoma
This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with relapsed / refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy
Lymphoma
II
Dholaria, Bhagirathbhai
NCT03768505
VICCPCL1913
